Five Prime Therapeutics, a clinical stage biotech developing protein therapeutics, announced terms for its IPO on Wednesday. The San Francisco, CA-based company plans to raise $52 million by offering 4.0 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Five Prime Therapeutics would command a market value of $198 million.
Five Prime Therapeutics, which was founded in 2001 and booked $26 million in collaboration revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol FPRX. The company initially filed confidentially on June 14, 2013. Jefferies, BMO Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.